Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 1:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 238 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pediatric Brain Tumors Clear all
Recruiting Phase 1 Interventional

GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults

NCT07087002
View directory record Official record
Conditions
Medulloblastoma, Central Nervous System Embryonal Tumor, Refractory Medulloblastoma, Recurrent Medulloblastoma, Pediatric Brain Tumor, Embryonal Tumor With Multilayered Rosettes (ETMR), Pineoblastoma, Atypical Teratoid/Rhabdoid Tumor (ATRT) of the CNS, CNS Neuroblastoma, FOXR2-activated
Interventions
GPC2-CAR T cells, Fludarabine, Cyclophosphamide
Biological · Drug
Lead sponsor
Stanford University
Other
Eligibility
1 Year to 30 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Jul 24, 2026, 1:19 AM EDT
Terminated Phase 1 Interventional

RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors

NCT04525014
View directory record Official record
Conditions
Brain Tumor, Recurrent, Brain Tumor, Pediatric, Central Nervous System Neoplasms, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
RRx-001, Temozolomide, Irinotecan
Drug
Lead sponsor
EpicentRx, Inc.
Industry
Eligibility
1 Year to 21 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Jul 24, 2026, 1:19 AM EDT
Completed Early Phase 1 Interventional

Methotrexate Infusion Into the Fourth Ventricle in Children With Malignant Fourth Ventricular Brain Tumors: A Pilot Study

NCT01737671
View directory record Official record
Conditions
Brain Tumor, Malignant Neoplasm of Fourth Ventricle of Brain
Interventions
Ommaya Reservoir, Methotrexate, Leucovorin
Procedure · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 22 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Jul 24, 2026, 1:19 AM EDT
Terminated Early Phase 1 Interventional

FET-PET/MRI for Surgical Assessment of Pediatric Brain Tumors

NCT03451123
View directory record Official record
Conditions
Pediatric Brain Tumors
Interventions
FET PET/MRI
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
6 Years to 18 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Jul 24, 2026, 1:19 AM EDT
Terminated Phase 2 Interventional Results available

High Dose Chemotherapy With Amifostine and Autologous Stem Cell Transplantation for High Risk Relapsed Pediatric Solid Tumors and Brain Tumors

NCT05167370
View directory record Official record
Conditions
Solid Tumors, Brain Tumors
Interventions
Amifostine
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Up to 30 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 24, 2022 · Synced Jul 24, 2026, 1:19 AM EDT
Completed Phase 2 Interventional Results available

Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors

NCT00024258
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer, Liver Cancer, Neuroblastoma, Ovarian Cancer, Retinoblastoma, Sarcoma
Interventions
arsenic trioxide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 40 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 24, 2015 · Synced Jul 24, 2026, 1:19 AM EDT
Completed Phase 2 Interventional Results available

Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma

NCT00883688
View directory record Official record
Conditions
Brain Cancer, Pediatric Cancers
Interventions
Bevacizumab, Lapatinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 21 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
6
States / cities
Stanford, California • Chicago, Illinois • Cincinnati, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2020 · Synced Jul 24, 2026, 1:19 AM EDT
Not yet recruiting Phase 2 Interventional

Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG).

NCT07680439
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma, DIPG, Brain Tumor, CNS Tumor, Central Nervous System Tumor, Pediatric Cancer, Adult Cancer Patients, CNS Tumor, Childhood, CNS Tumor, Adult, Brainstem Glioma, Diffuse Midline Glioma, DMG
Interventions
BCB-276
Biological
Lead sponsor
BrainChild Bio, Inc
Industry
Eligibility
1 Year to 26 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
6
States / cities
Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 24, 2026, 1:19 AM EDT
Suspended Not applicable Interventional

Brain MRF in Children, Adolescents and Young Adults With Acute Leukemia

NCT06421155
View directory record Official record
Conditions
Acute Leukemia, Acute Lymphoblastic Leukemia, Pediatric, Acute Myeloid Leukemia in Children, Myeloproliferative Neoplasm
Interventions
MRF with neurocognative studies
Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
Up to 30 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jul 24, 2026, 1:19 AM EDT
Completed No phase listed Observational

Components of Social Functioning in Survivors of Pediatric Brain Tumors

NCT03361033
View directory record Official record
Conditions
Brain Tumor, Pediatric, Medulloblastoma, Pediatric
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
8 Years to 12 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Jul 24, 2026, 1:19 AM EDT
Recruiting Phase 2 Interventional

PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma

NCT05096481
View directory record Official record
Conditions
High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Recurrent Medulloblastoma
Interventions
PEP-CMV, Temozolomide, Tetanus Diphtheria Vaccine
Biological · Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
3 Years to 39 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
13
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Jul 24, 2026, 1:19 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of MEK162 for Children With Low-Grade Gliomas

NCT02285439
View directory record Official record
Conditions
Low-Grade Gliomas, Malignant Neoplasms, Brain, Soft Tissue Neoplasms
Interventions
MEK162
Drug
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
1 Year to 18 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Jul 24, 2026, 1:19 AM EDT
Completed Phase 1 Interventional

Study of GDC-0084 in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma or Diffuse Midline Gliomas

NCT03696355
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
GDC-0084, radiation therapy
Drug · Radiation
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
2 Years to 21 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 17, 2023 · Synced Jul 24, 2026, 1:19 AM EDT
Active, not recruiting Not applicable Interventional

Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan for Patients With High Grade Glioma

NCT03739372
View directory record Official record
Conditions
Glioma, Glioma of Brain, Cancer, Pediatric Cancer, Pediatric Brain Tumor, Astrocytoma, Glioblastoma, Hemispheric
Interventions
Specialized tumor board recommendation
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
Up to 21 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
12
States / cities
San Diego, California • San Francisco, California • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Jul 24, 2026, 1:19 AM EDT
Completed Phase 2 Interventional Results available

A Trial of Poly-ICLC in the Management of Recurrent Pediatric Low Grade Gliomas

NCT01188096
View directory record Official record
Conditions
Brain Tumors
Interventions
Poly ICLC
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Up to 21 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
2
States / cities
San Diego, California • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 11, 2023 · Synced Jul 24, 2026, 1:19 AM EDT
Completed Phase 1 Interventional

Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain Tumors

NCT02444546
View directory record Official record
Conditions
Childhood Astrocytoma, Childhood Atypical Teratoid/Rhabdoid Tumor, Diffuse Intrinsic Pontine Glioma, Glioma, Recurrent Childhood Anaplastic Oligodendroglioma, Recurrent Childhood Brain Neoplasm, Recurrent Childhood Glioblastoma, Recurrent Childhood Medulloblastoma, Recurrent Primitive Neuroectodermal Tumor, Refractory Brain Neoplasm
Interventions
Laboratory Biomarker Analysis, Sargramostim, Wild-type Reovirus
Other · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
10 Years to 21 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 23, 2023 · Synced Jul 24, 2026, 1:19 AM EDT
Completed Phase 2 Interventional

Phase 2 Study of Nimotuzumab in Pediatric Recurrent Diffuse Intrinsic Pontine Glioma

NCT00600054
View directory record Official record
Conditions
Recurrent Diffuse Pontine Gliomas
Interventions
nimotuzumab (anti EGFR humanized monoclonal antibody)
Biological
Lead sponsor
YM BioSciences
Industry
Eligibility
3 Years to 18 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
10
States / cities
Denver, Colorado • Washington D.C., District of Columbia • Gainesville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2011 · Synced Jul 24, 2026, 1:19 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Study of Brain Tumors (Tectal Tumors) Using Magnetic Resonance Imaging

NCT00229814
View directory record Official record
Conditions
Tectal Plate Glioma
Interventions
Not listed
Lead sponsor
Children's Healthcare of Atlanta
Other
Eligibility
4 Years to 18 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 23, 2012 · Synced Jul 24, 2026, 1:19 AM EDT
Recruiting Not applicable Interventional

Feasibility/Acceptability of Attentional-Control Training in Survivors

NCT05528939
View directory record Official record
Conditions
Pediatric Cancer, Pediatric ALL, Pediatric Brain Tumor, Attention Difficulties, Cognitive Deficit in Attention
Interventions
EndeavorRx, Control video game
Device · Other
Lead sponsor
Children's National Research Institute
Other
Eligibility
8 Years to 16 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 9, 2025 · Synced Jul 24, 2026, 1:19 AM EDT
Completed Not applicable Interventional

Neuroplasticity-Based Cognitive Remediation for Pediatric Brain Tumor Survivors

NCT02129712
View directory record Official record
Conditions
Brain Tumor
Interventions
Cognitive training
Behavioral
Lead sponsor
Vanderbilt University
Other
Eligibility
7 Years to 16 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Jul 24, 2026, 1:19 AM EDT
Terminated No phase listed Observational

Testing Cerebrospinal Fluid for Cell-free Tumor DNA in Children, Adolescents, and Young Adults With Brain Tumors

NCT05934630
View directory record Official record
Conditions
Anaplastic Astrocytoma, Diffuse Brainstem Glioma, Glioblastoma Multiforme, High-grade Astrocytoma NOS, Fibrillary Astrocytoma, Low-Grade Astrocytoma, Nos, Pilocytic Astrocytoma, Choroid Plexus Carcinoma, CNS Primary Tumor, Nos, Atypical Teratoid/Rhabdoid Tumor, Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, Ependymoma, NOS, Anaplastic Oligodendroglioma, Oligodendroglioma, Nos, CNS Germ Cell Tumor, Pineoblastoma, Diffuse Leptomeningeal Glioneuronal Tumor
Interventions
Not listed
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
Up to 40 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
9
States / cities
Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Jul 24, 2026, 1:19 AM EDT
Terminated Phase 1 Interventional

Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I)

NCT03396575
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma (DIPG), Brain Stem Glioma
Interventions
TTRNA-DC vaccines with GM-CSF, TTRNA-xALT, Cyclophosphamide + Fludarabine Lymphodepletive Conditioning, Dose-Intensified TMZ, Td vaccine, Autologous Hematopoietic Stem Cells (HSC)
Biological · Drug
Lead sponsor
University of Florida
Other
Eligibility
3 Years to 30 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Jul 24, 2026, 1:19 AM EDT
Terminated Phase 2 Interventional

A Study of Panobinostat in Pediatric Patients With Solid Tumors Including MRT/ATRT

NCT04897880
View directory record Official record
Conditions
Rhabdoid Tumor, Atypical Teratoid/Rhabdoid Tumor, Malignant Rhabdoid Tumor, Recurrent Brain Tumor, Childhood
Interventions
Panobinostat
Drug
Lead sponsor
Australian & New Zealand Children's Haematology/Oncology Group
Other
Eligibility
Up to 39 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 23, 2025 · Synced Jul 24, 2026, 1:19 AM EDT
Completed Early Phase 1 Interventional Results available

Donepezil in Treating Young Patients With Primary Brain Tumors Previously Treated With Radiation Therapy to the Brain

NCT00452868
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Cognitive/Functional Effects, Long-term Effects Secondary to Cancer Therapy in Children, Neurotoxicity, Psychosocial Effects of Cancer and Its Treatment, Radiation Toxicity
Interventions
Donepezil
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
8 Years to 17 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
Boston, Massachusetts • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 6, 2018 · Synced Jul 24, 2026, 1:19 AM EDT